secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2023-03-24T23:59:59+00:00
Accession:  0001104659-23-036246
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics FY2022 net loss $54.6M; cash $65.5M plus $50M from Flame acquisition
--------------------------------------------------------------------------------

- Net loss $54.6M for 2022 (vs $40.6M in 2021); R&D expenses $45M (vs $32.2M).
- Cash $65.5M at Dec 31, 2022; excludes ~$50M cash from Flame acquisition in Jan 2023.
- Flame acquisition: issued ~19.8M common shares + 136.8k preferred convertible into 136.8M common shares (subject to approval).
- DKN-01: Part C DisTinGuish randomized trial enrollment expected completion late 2023; Part A DeFianCe CRC study enrollment near completion.
- BeiGene's option for DKN-01 in Asia expired; clinical collaboration continues for DisTinGuish Part C.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923036246/0001104659-23-036246-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923036246/tm2310372d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-036246

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer